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Spontaneous intracerebral hemorrhage (SICH) is the most lethal type of stroke. Half of 
these deaths occur within the acute phase. Frequently observed deterioration during 
the acute phase is often due to rebleeding or peri-hematomal expansion. The exact 
pathogenesis that leads to rebleeding or peri-hemorrhagic edema remains under much 
controversy. Numerous trials have investigated potential predictor of  peri-hemorrhagic 
edema formation or rebleeding but have yet to come with consistent results. Unfortunately, 
almost all of the “classical” approaches have failed to show a significant impact in regard 
of significant clinical outcome in randomized clinical trials. Current treatment strategies 
may remain “double-edged swords,” for inherent reasons to the pathophysiology of sICH. 
Therefore, the right balance and possibly the combination of current accepted strategies 
as well as the evaluation of future approaches seem urgent. This article reviews the 
role of disturbed autoregulation following SICH, surgical and non-surgical approaches 
in management of SICH, peri-hematoma edema, peri-hematoma expansion, and future 
therapeutic trends.
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inTRODUCTiOn
Spontaneous intracerebral hemorrhage (sICH) accounts for approximately 13–17% of all strokes; 
however, sICH carries substantial mortality and morbidity, approaching approximately 50% within 
3 months and severe disability in the majority of survivors. Half of these deaths occur within the acute 
phase (1). Neurological deterioration during the acute phase may be due to hematoma expansion or 
peri-hemorrhagic edema growth (2). Since hematoma growth tends to occur within the first 24 h and 
edema formation within the first 72 h from symptoms onset, intervention during this time period 
may modify long-term outcome (2). Thus, the dynamic nature of early sICH represents a manage-
ment challenge and opportunity for intervention. In this review, we discuss the pathogenesis and 
the role of different proposed pathways that have been explored to contribute to sICH progression.
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PATHOGeneSiS
Biology
The pathophysiology leading to hematoma expansion and edema 
progression remains poorly understood. sICH is believed to 
result from rupture of lipohyalinoic arteries followed by second-
ary arterial rupture at the periphery of the enlarging hematoma, 
in an “avalanche” fashion (2). This model was first proposed by 
C. Miller Fisher in the early 1970s (2, 3). Hematoma expansion 
may reflect additional leakage, extended spatial distribution of 
the initial hemorrhage, or both. Based on this model, mechanical 
disruption may be considered the most important neuropatho-
logical correlate for the expanding hematoma (2). Hematoma 
expansion leads to secondary injury mechanisms, which accentu-
ates tissue destruction. Yet, exact pathophysiological mechanisms 
are unclear.
Prediction of risk factors for hematoma expansion and 
subsequent secondary injury might provide a first step toward 
development of effective therapies. Hematoma expansion and 
edema generation do not appear related to a single mechanistic 
pathway or risk factor, but rather several pathways/factors 
thought to act in synergy. Early preclinical models proposed 
the concept of “peri-hemorrhagic ischemia” surrounding the 
primary hematoma (2, 4–7). However, subsequent metabo-
lism and flow studies demonstrated that such peri-hematoma 
changes were far from universal (7–10). Perihematomal 
changes lead to cytotoxic edema and neuroinflammatory 
mediators (11, 12).
Role of Disturbed inflammation
Numerous human and preclinical studies suggest a link between 
inflammation, peri-hematoma edema formation, and hematoma 
expansion. These studies particularly shed light on a direct role 
of neutrophil activation, free-radical formation, and the expres-
sion of interleukin-6 (IL-6) and tumor-necrosis alpha (TNF-α) 
(13–15). Several rat model studies have also shown that formation 
of the peri-hemorrhagic penumbra can be mediated by various 
neuroprotective elements such as N-methyl-d-aspartate receptor 
antagonism. The latter blunts excitatory amino acid-mediated 
neuronal death and diminishes microglia-mediated neuronal 
injury (11, 12, 16). Studies have also linked elevated plasma 
concentration of cellular fibronectin (c-FN) and inflammatory 
mediators IL-6 and TNF-α in the early phase of hematoma 
enlargement (13–15). However, the clinical utility of matrix 
metalloproteinase (MMP), c-FN, TNF-α, or IL-6 blood concen-
trations in early ICH remains unclear. Another distinct pathway 
that supports the role of neuro-inflammation in hematoma 
expansion includes thrombin-induced activation of inflamma-
tory cascade; the latter being an important regulator of cellular 
activation through binding to the protease-activated receptors 
(PARs) expressed on platelets, leukocytes, and endothelial cells 
(ECs) (17–20), along overexpression of MMP (17–19). The latter 
promotes extracellular matrix proteolysis, attack the basal lamina, 
and results in degradation of c-Fn (17–19, 21). The expression of 
such inflammatory processes seem to coincide chronologically 
with the peak of peri-hemorrhagic edema formation and second-
ary hematoma expansion; when its maximal potential is often 
reached by 3–5 days from the initial ictus of hematoma formation 
(2, 10, 22, 23).
Role of Disturbed Autoregulation
Disturbed autoregulation and uncontrolled perfusion pres-
sure in hypertension may act as a driving force for hematoma 
expansion and peri-hemorrhagic edema formation. Numerous 
studies have suggested that blood pressure elevation may worsen 
ICH by providing continued force for hematoma expansion and 
potentially worsening outcomes (24, 25). However, aggressively 
blood pressure lowering after sICH may be counterintuitive. 
Elevation in mean arterial pressure may be a natural response 
to preserve cerebral perfusion. Qureshi et  al. (26) describe 
three distinct phases of metabolic changes with respect to 
autoregulation: hibernation, seen during the first 48  h with 
reduction of CBF, and metabolism occurring in bilateral cer-
ebral hemispheres; reperfusion, which may last up to 14  days 
with heterogeneous areas of cerebral hypo- and hyperperfusion; 
and finally, normalization, with resolution and development of 
normal cerebral flow pattern except in non-viable brain tissue 
(3, 26–32). Numerous models demonstrated that acute blood 
pressure reduction is associated with decreased diffusion on 
brain imaging (21, 33). However, studies have found no clear 
clinical implication of these findings (34, 35). Major randomized 
clinical trials (ATACH, INTERACT, and INTERACT-2) have 
explored the relationship of blood pressure reduction and clini-
cal outcomes in ICH. While no sustained long term outcome 
benefit has been found for aggressive blood pressure manage-
ment, interventions do appear to be safe (36–38). More recently, 
the ATACH 2 trial further re-affirmed that intense BP control 
(target 110–139 mmHg) did not result in an incremental benefit 
or lower rate of death or disability than standard reduction to a 
target of 140–179 mmHg (21, 33–35, 39).
Role of Hemostasis
While homeostatic therapies seem promising, through preven-
tion of hematoma enlargement, clinical trials examining use of 
blood products (in particular recombinant factor VIIa) remains 
inconclusive. While initial preliminary data suggested that Factor 
VIIa may be safe (40, 41), results from a phase-3 randomized 
controlled trial showed that although recombinant factor VIIa 
use after ICH resulted in significant reduction in hematoma 
volume but no reduction in severe disability or death compared 
to placebo at 3 months (42). If fact, recombinant factor VIIa use 
after ICH was associated with higher risk of arterial thrombo-
embolic adverse events (43). The current AHA/ASA guidelines 
have since concluded that recombinant factor VIIa remains 
investigational and should not be used in sICH (44). While 
there is no disagreement in regard of coagulopathy reversal for 
patients’ who develop acute intracerebral hemorrhage while on 
anticoagulant therapy, the role of platelet transfusion remains 
controversial. A recent multicenter randomized controlled trial 
suggested (PATCH) suggested that platelet transfusion is infe-
rior to standard of care for patients who develop intracerebral 
hemorrhage while on antiplatelet therapies, and thus cannot be 
recommended (45).
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Surgical Hematoma evacuation
Surgical evacuation of the hematoma, and on whether this is 
beneficial, remains under investigation. Under select circum-
stances, various surgical approaches may be undertaken. This 
may include conventional craniotomy, stereotactic guidance 
with aspiration and thrombolysis, image-guided stereotactic 
endoscopic aspiration, and decompressive craniectomy. The 
overall aim of surgical intervention is to remove the source of 
hemorrhage, eliminate the localized or global mass effect of the 
hematoma, and eliminate the toxic effects of blood degradation 
products. To date, two major randomized controlled trials 
(STITCH I and STICH-II) explored surgical vs non-surgical 
management of ICH (46, 47). However, those trials failed to 
show an outcome benefit over conservative treatment. However, 
one of the largest meta-analysis which also included the 
STICH-II data suggested an overall benefit for surgery for select 
subgroups of patients, including those with poorer prognosis at 
presentation, those with secondary deterioration attributed to 
hematoma expansion, and those with superficial ICH without 
intraventricular extension (48).
Recently, minimally invasive and stereotactic surgeries have 
emerged as an alternative to craniotomy for hematoma evacu-
ation. The more recently published ICES (intraoperative stereo-
tactic computed tomography-guided endoscopic surgery) study 
suggested that early computerized tomographic image-guided 
endoscopic surgery is a safe and effective method in select cases 
to remove acute intracerebral hematomas, with a potential to 
enhance neurological recovery (49). Similarly, the MISTIE trial 
(minimally invasive surgery plus alteplase) in intracerebral hem-
orrhage evacuation appeared overall safe and promising in ICH 
(50). However, many questions remain regarding the surgical 
optimization of the endoscopic technique, the patients’ selection, 
and the timing of surgery. The role of minimally and endoscopic 
surgery will continue to evolve as more centers continue to gain 
experience with this promising approach.
COnCLUSiOn
Current treatment strategies may remain “double-edged swords.” 
For example; surgical intervention may reduce hematoma 
volume but may also lead to decompression of the surrounding 
“peri-hemorrhagic penumbra tissue” with subsequent re-accu-
mulation of bleeding. Likewise, hemostasis might stop cerebral 
bleeding yet compromise normal circulation. Blood pressure 
reduction decreases hematoma expansion but may also decrease 
cerebral perfusion and other vital organ blood flow. Therefore, 
balance of current accepted strategies and the evaluation of future 
approaches seem critical. This topic will continue to evolve as 
our understanding of the pathogenesis of sICH and secondary 
hematoma expansion continue to evolve.
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